seems shift to panacea biotec is better.......

EPS for 2011 will be 38+ and for 2012 will be 45+...

qrtly results on 31oct,saturday2009-10 rs300crore expansion at dahez sez read economictimes use google ...

Hi Guys, Wockhardt immediate target is 220 in next few days. Support at around 160 levels, will be giving good upside potential in the coming days even if the market corrects from these levels. One year target at 300. After Banking and Auto its time for Pharma sector to catch up. Thanks....

this is a clear mkt driven speculation......... Merind will not be sold . Its a core business and only unit in india which has technology capabilities. hence sure wock will not put it on sale........... And there is no need for this also. The pressure was from FCCB, it will be adjusted with the recent sales. Premium will be adjusted from provision made earlier. Hence total around 700 crs debt will be repaid by october 2009. Out of 3200 crs restructured debt , 700 crs will be repaid. Hence Debt / equity will be at around 2.5:1 by the end of this FY-2009-10 (there is excluding its foreign subsideries LBO borrowing as the same will be repaid by them only). Wockhardt will come out with robust results form next fiscal 2010-11. ...

I will let you know the facts.... You might have assumed intrest coat at around 300-350 crs. But see dear it will be at 200-250 crs maximum as the zero coupen bonds have been issued. and there is no much repayments till 5 years. Hence there will not be much negatives from EBITDA. i predict ebitda of 1000+ crs for 2012 (including these FTf`s)hence even 500 crs is to be considered for ..... then pat will be at 500 crs. hence eps will be at 45-50 range. wock will be at 1000+ once again by 2012....

can u give these BV,debt,reserves and why cashflow will comedown, how u decided for an eps of 30 for 2013. interpretate.....................

every script there is a broker behind and value in it,becuz i was one of the person who applied IPO in 1992 december 5th , so cool promotor have good cash background that saving wockhardt and in is internal news between banks and promotor,this quarter they show but coming quarters they will perform to lift share price and sell the stock to qip or fii or other issues that they can pay debt and debt equity ratio will come down to 1:1 thats what promotors want never miss this stock when dips below 170...

q2 60% down in intreast cost,in 2yrs sales rs1200cr plus imagine NPM @ 7% Equals to net profit around Rs50-80 crores include future zero debt company,expecting eps avg@ rs35 conservatively,small investors below 1-500shares are 85% of the stock good luk happy investing, ...

qrtly results on 31oct,saturday2009-10
rs300crore expansion at dahez sez read economictimes use google ...

it is my general calculation,i am waiting for some clear pictures in medicinal values and looking part of ftf dcf values and company management internal planning is boosting share price saving sg&a and other expenses to show maximum share value to dilute the equity later on clear the balance sheet,thats what i calculated becuz no brokerage is concluded any research report untill management comeup with clear picture of restructuring business,my self assuming enterprise value and eps 30 minimum by 2013 and one can expect more on dcf value....

To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis as per clause 41 of the Listing Agreement for the quarter and half year ended on September 30, 2009....

Torrent Group to expand pharma facility, set up SEZ
29 Sep 2009, 0043 hrs IST, Himanshu Darji, ET Bureau

AHMEDABAD: It’s all about expansion at Torrent Group, which has interests in pharma and power. Besides chalking out ambitious Rs 4,500-crore plans
for Torrent Power, the group is also expanding its Kadi-based pharma facility and setting up a green field project at upcoming Dahej SEZ.

To expand its existing Indrad facility at Kadi in Mehsana district, Torrent Pharma has approached the regulatory authorities. On the other hand, proposed Dahej SEZ’s unit approval committee has already given nod to Torrent Pharma to set up a formulation and bulk drug manufacturing facility.

Soon, it will start civil work at its 1.64 lakh sq mt land at SEZ where it is also a co-developer with plans to set up 1,500 MW power plant. Torrent Group will pump in close to Rs 300 crore for pharma unit and Rs 4,500 crore for power unit.

Dahej SEZ CEO RJ Shah confirmed that the unit approval committee has cleared the path for Torrent Pharma. However, company officials could not be reached for their comments.

According to the sources close to the developments, Dahej is emerging as a major growth centre for Torrent Group that will have presence through both of its business arms and also eyeing the city gas distribution. It is going to acquire close to 14 lakh sq mt land in Dahej SEZ for power and pharma units.

“Torrent Pharma was considering modest investments in Dahej with facility to manufacture formulations only. Subsequently, it has revised its plans to invest close to Rs 300 crore for both formulations and bulk drug manufacturing. Torrent Pharma is aiming to strengthen its position in the exports market of the US and Europe.

He added that Torrent Pharma would kick of expansion at its Indrad facility as soon as it receives necessary clearances from the authorities.

Indrad facility was set up in 1989 and it complies with WHO, GMP, MHRA and TGA norms. At Indrad, Torrent Pharma has capacity to manufacture 6,000 million tablets, capsules and vials and 15,000 kg of bulk drugs a year.

Torrent Pharma has tied up with Novo Nordisk since August 2005 and part of its parenteral facility is dedicated for the formulation and packaging of insulin, exclusively for Novo Nordisk.
...

To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis as per clause 41 of the Listing Agreement for the quarter and half year ended on September 30, 2009....